The Pharma and Biotech Daily: Beckley's Nasal Spray Success, M&A Activity Surge, and Job Opportunities

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Beckley's psychedelic nasal spray, BPL-003, has successfully cleared Phase II trials for treatment-resistant depression, showing robust efficacy data. Analysts predict the asset could reach peak market sales of $1 billion. This paves the way for late-stage development and a proposed merger with atai life sciences. In other news, M&A activity saw a significant increase in June, with big pharmas like Eli Lilly, Sanofi, and Novartis making multiple deals. The FDA's decision to remove risk evaluation and mitigation strategies from approved CAR T cancer therapies has been well-received by the cell and gene therapy community. Additionally, Argenx has made a $1.5 billion acquisition of Unum Therapeutics' macrocyclic peptides, aimed at "undruggable" targets. Moderna, Merck, UroGen, and other companies received regulatory nods for various treatments in June. Evotec is hosting a webinar on preserving quality in the pharma industry amidst financial challenges on July 16. Job opportunities in the industry include positions at Biomarin Pharmaceutical Inc., Regeneron Pharmaceuticals, and AbbVie.